+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug (Vitamin E & Pioglitazone, Resmetirom), By Disease Stage, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 110 Pages
  • November 2024
  • Region: Global
  • Grand View Research
  • ID: 6032418
Description Jump to:
The global non-alcoholic steatohepatitis treatment market size is expected to reach USD 33.80 billion by 2030, registering a CAGR of 28.1% from 2025 to 2030. The non-alcoholic steatohepatitis (NASH) treatment market is primarily driven by the launch of drugs such as Novo Nordisk's Ozempic, Intercept's Ocaliva, and Inventiva's lanifibranor, among others.

The NASH treatment market has major unmet needs owing to factors such as the unavailability of approved drugs, high disease burden, and complex diagnostic procedures. Currently, the market is dominated by off-label drugs such as Pioglitazone and Vitamin E. These are widely prescribed drugs in this space globally. However, to address the unmet opportunity, key market players are heavily investing in R&D activities to develop novel therapeutics for NASH treatment. Currently, there are more than 50 pipeline candidates.

Some of the late-stage pipeline candidates expected to launch during the forecast period include Inventiva Pharma's Lanifibranor, Intercept Pharmaceuticals' Obeticholic acid, Galmed Pharmaceuticals Ltd.'s Aramchol, Novo Nordisk A/S's Semaglutide, and Madrigal Pharmaceuticals, Inc.'s Resmetirom. Among these, Intercept Pharmaceuticals's Obeticholic Acid (OCA), and Madrigal Pharmaceuticals, Inc.'s Resmetirom, are the most looked upon drugs and are expected to enter comparatively earlier than other pipeline candidates.

Research studies reveal that non-alcoholic steatohepatitis is strongly associated with obesity and diabetes. Research studies show that around 80% of NASH patients are obese. In countries such as the U.S., the obesity prevalence is as high as 42%, according to the latest 2021 statistics by CDC. In addition, countries such as the U.S. and Japan account for the highest prevalence of non-alcoholic steatohepatitis globally, and these countries also have a high burden of obesity and diabetes. All such factors will fuel the NASH treatment market throughout the forecast period.

Strategic initiatives by pharma giants and supportive regulatory authority policies such as fast track designation are further expected to accelerate the market growth. In May 2022, Pfizer, Inc.'s Ervogastat/Clesacostat Combination therapy received fast track designation. This is one of the potential drug combinations for the treatment of non-alcoholic steatohepatitis. Such drug designation boosts the clinical trial process for drugs.

Liver biopsy is the gold standard for the diagnosis of non-alcoholic steatohepatitis. The invasive nature of this diagnostics test limits its usage to only symptomatic cases, and as a result, the global average diagnostic rate for NASH is around 20%. The unavailability of biomarkers-based non-invasive tests for the diagnosis of non-alcoholic steatohepatitis is expected to impede the market growth.

Non-alcoholic Steatohepatitis Treatment Market Report Highlights

  • Vitamin E and Pioglitazone (Off-label) acted as the lone contributor with a 100% share of the market in 2024. This can be attributed to the unavailability of approved drugs in the market
  • The retail and specialty pharmacies segment held a share of 63.8% in 2024. Retail and specialty pharmacies are more compatible with chronic diseases such as NASH, where the patients are more commonly associated with homecare settings
  • North America dominated the overall NASH treatment space in terms of revenue. This can be attributed to increased disease awareness, better healthcare facilities, and comparatively higher treatment rate than in other regions

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Disease Stage
1.2.3. Distribution channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug and disease stage outlook
2.2.2. Distribution channel outlook
2.3. Competitive Insights
Chapter 3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidence of Non-Alcoholic Steatohepatitis (NASH) disease
3.2.1.2. Rising awareness about disease
3.2.1.3. Robust product pipeline and rising R&D
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Stringent regulations
3.3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pipeline Analysis
Chapter 4. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Movement Analysis
4.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Drug, Revenue (USD Million)
4.4. Bronchodilators
4.4.1. Vitamin E and Pioglitazone market estimates and forecasts 2018 - 2030 (USD Million)
4.5. Obeticholic Acid (OCA)
4.5.1. Obeticholic Acid (OCA) market estimates and forecasts 2018 - 2030 (USD Million)
4.6. Lanifibranor
4.6.1. Lanifibranor market estimates and forecasts 2018 - 2030 (USD Million)
4.7. Semaglutide
4.7.1. Semaglutide market estimates and forecasts 2018 - 2030 (USD Million)
4.8. Resmetirom
4.8.1. Resmetirom market estimates and forecasts 2018 - 2030 (USD Million)
4.9. Aramchol
4.9.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
4.10. Aramchol
4.10.1. Aramchol market estimates and forecasts 2018 - 2030 (USD Million)
4.11. Cenicriviroc
4.11.1. Cenicriviroc market estimates and forecasts 2018 - 2030 (USD Million)
4.12. Other Drugs
4.12.1. Other drugs market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Movement Analysis
5.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Disease Stage, Revenue (USD Million)
5.4. NASH Stage F0
5.4.1. NASH stage F0 market estimates and forecasts 2018 - 2030 (USD Million)
5.5. NASH Stage F1
5.5.1. NASH stage F1 market estimates and forecasts 2018 - 2030 (USD Million)
5.6. NASH Stage F2
5.6.1. NASH stage F2 market estimates and forecasts 2018 - 2030 (USD Million)
5.7. NASH Stage F3
5.7.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)
5.8. NASH Stage F3
5.8.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Movement Analysis
6.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
6.4. Hospitals Pharmacies
6.4.1. Hospitals pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
6.5. Retail and Specialty Pharmacies
6.5.1. Retail and Specialty Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
6.6. Other Pharmacies
6.6.1. Other pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Regional Estimates & Trend Analysis By Product, Application, and End Use
7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company market share analysis, 2024
8.3.2. Intercept Pharmaceuticals, Inc.
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Galmed Pharmaceuticals Ltd.
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Inventiva.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. AbbVie Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Galectin Therapeutics Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Madrigal Pharmaceuticals Inc (Madrigal).
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. NGM Biopharmaceuticals, Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Novo Nordisk A/S
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. The Bristol-Myers Squibb Company
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Gilead Sciences, Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 List of Secondary Sources
Table 3 List of Abbreviation
Table 4 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
Table 5 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 6 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 7 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 8 U.S. Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 9 U.S. Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 10 U.S. Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 11 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 12 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Disease Stage, 2018 - 2030 (USD Million)
Table 13 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 14 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 15 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Disease Stage, 2018 - 2030 (USD Million)
Table 16 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 17 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
Table 18 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 19 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 20 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 21 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 22 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 23 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 24 UK Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 25 UK Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 26 UK Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 27 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 28 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 29 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 30 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 31 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 32 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 33 Spain Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 34 Spain Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 35 Spain Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 36 Denmark Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 37 Denmark Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 38 Denmark Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 39 Sweden Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 40 Sweden Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 41 Sweden Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 42 Norway Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 43 Norway Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 44 Norway Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 45 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 49 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 50 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 51 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 52 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 53 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 54 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 55 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 56 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 57 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 58 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 59 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 60 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 61 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 62 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 63 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 64 Thailand Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 65 Thailand Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 66 Thailand Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 67 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
Table 68 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 69 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 70 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 71 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 72 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 73 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 74 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 75 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 76 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 77 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
Table 78 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 79 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 81 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 84 South Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 85 South Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 86 South Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 87 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 88 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 89 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
Table 90 Kuwait Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
Table 91 Kuwait Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
Table 92 Kuwait Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Non-Alcoholic steatohepatitis (NASH) treatment market Segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Non-alcoholic steatohepatitis (NASH) treatment market snapshot
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Non-alcoholic steatohepatitis (NASH) treatment market driver impact
Fig. 14 Non-alcoholic steatohepatitis (NASH) treatment market restraint impact
Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 16 Industry Analysis - Porter's Five Forces
Fig. 17 Strategy mapping
Fig. 18 Non-alcoholic steatohepatitis (NASH) treatment market: Drug outlook and key takeaways
Fig. 19 Non-alcoholic steatohepatitis (NASH) treatment market: Drug movement analysis & market share 2024 & 2030
Fig. 20 Vitamin E and Pioglitazone non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Obeticholic Acid non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Lanifibranor non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Semaglutide non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Resmetirom non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Aramchol non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Cenicriviroc non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Other drugs non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Non-alcoholic steatohepatitis (NASH) treatment market: Disease stage outlook and key takeaways
Fig. 29 Non-alcoholic steatohepatitis (NASH) treatment market: Disease stage movement analysis & market share 2024 & 2030
Fig. 30 NASH F0 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 NASH F1 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 NASH F2 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 NASH F3 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 NASH F4 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Non-alcoholic steatohepatitis (NASH) treatment market: Distribution channel outlook and key takeaways
Fig. 36 Non-alcoholic steatohepatitis (NASH) treatment market: Distribution channel movement analysis & market share 2024 & 2030
Fig. 37 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Retail and specialty pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Global Non-Alcoholic Steatohepatitis (NASH) Treatment market: Regional movement analysis
Fig. 41 Global Non-Alcoholic Steatohepatitis (NASH) Treatment market: Regional outlook and key takeaways
Fig. 42 Global Non-Alcoholic Steatohepatitis (NASH) Treatment market share and leading players
Fig. 43 North America, by country
Fig. 44 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 U.S. key country dynamics
Fig. 46 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Canada key country dynamics
Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Mexico key country dynamics
Fig. 50 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 UK key country dynamics
Fig. 53 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Germany key country dynamics
Fig. 55 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 France key country dynamics
Fig. 57 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Italy key country dynamics
Fig. 59 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Spain key country dynamics
Fig. 61 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Denmark key country dynamics
Fig. 63 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Sweden key country dynamics
Fig. 65 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Norway key country dynamics
Fig. 67 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 China key country dynamics
Fig. 70 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Japan key country dynamics
Fig. 72 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 India key country dynamics
Fig. 74 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Thailand key country dynamics
Fig. 76 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 South Korea key country dynamics
Fig. 78 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Australia key country dynamics
Fig. 80 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Brazil key country dynamics
Fig. 83 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Argentina key country dynamics
Fig. 85 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 South Africa key country dynamics
Fig. 88 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Saudi Arabia key country dynamics
Fig. 90 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 UAE key country dynamics
Fig. 92 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Kuwait key country dynamics
Fig. 94 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Market share Analysis of key market players, 2024

Companies Mentioned

  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals Ltd
  • Inventiva
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc (Madrigal)
  • NGM Biopharmaceuticals, Inc.
  • Novo Nordisk A/S
  • The Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages110
PublishedNovember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 7.72 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.8 Billion
Compound Annual Growth Rate28.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Application, and Sales Channel - Product Image

Global Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Application, and Sales Channel

  • Report
  • 178 Pages
  • Global
From
Japan Non-Alcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2032 - Product Image

Japan Non-Alcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast - 2032

  • Report
  • 267 Pages
  • Japan
From
Global Non-Alcoholic Steatohepatitis Market (by Drug Type, Application Type, Distribution Type, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027) - Product Image

Global Non-Alcoholic Steatohepatitis Market (by Drug Type, Application Type, Distribution Type, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)

  • Report
  • 130 Pages
  • Global
From
Non-alcoholic Steatohepatitis (NASH) - Global Strategic Business Report - Product Image

Non-alcoholic Steatohepatitis (NASH) - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Non-Alcoholic Steatohepatitis Market: Analysis By Drug Type, By Application Type, By Distribution Type, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027 - Product Image

Non-Alcoholic Steatohepatitis Market: Analysis By Drug Type, By Application Type, By Distribution Type, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027

  • Report
  • 130 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.